Trial reportJournal of veterinary internal medicine2016
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Trial report in Journal of veterinary internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 1 synthesis or guideline pooled it, 313 citations in OpenAlex.
- ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.Journal of veterinary internal medicine · 2019Guideline
- Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.Journal of veterinary science · 2018Trial
- Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.Journal of veterinary internal medicine · 2018Trial
- Intranasal Midazolam versus Rectal Diazepam for the Management of Canine Status Epilepticus: A Multicenter Randomized Parallel-Group Clinical Trial.Journal of veterinary internal medicine · 2017Trial
- Evaluation of serum pancreatic lipase activity in dogs with myxomatous mitral valve disease.Journal of veterinary internal medicine · 2026Article
- Pre-anaesthetic risk assessment and management of dogs with myxomatous mitral valve disease: a spectrum of care narrative review.The Journal of small animal practice · 2026Review
- Exploratory Evaluation of Cardiac Fatty Acid-Binding Protein (H-FABP), Troponin I, NT-proBNP, Echocardiography, and Holter Monitoring for the Assessment of Doxorubicin-Induced Cardiac Damage in Dogs.Veterinary sciences · 2026Article
- Canine radiography and echocardiography sensor fusion for deep learning-based detection and classification of myxomatous mitral valve disease.Journal of thoracic disease · 2026Article
- Outcomes Associated with Mitral Regurgitation Reduction and Myocardial Work After Transcatheter Edge-to-Edge Repair of a Mitral Valve in Dogs.Veterinary sciences · 2026Article
- From prototype to veterinary patient: a pharmacokinetic clinical trial of 3D-printed pimobendan tablets in beagle dogs.Drug delivery and translational research · 2026Article
- Effect of pimobendan on mitral annular dynamics and mitral regurgitation in dogs with myxomatous mitral valve disease as determined by cardiac computed tomography.Journal of veterinary internal medicine · 2026Article
- Short-term effects of pimobendan in dogs with preclinical myxomatous mitral valve disease.Frontiers in veterinary science · 2026Article
- Urinary sodium indices do not reliably differentiate stage B2 myxomatous mitral valve disease in dogs from healthy dogs.Frontiers in veterinary science · 2026Article
- Clinical utility of point-of-care lactate measurement for assessing management status and prognosis in dogs with myxomatous mitral valve disease.Frontiers in veterinary science · 2026Article
- Characterization of global and regional left heart function using advanced echocardiography following intravenous administration of pimobendan in awake dogs.Frontiers in veterinary science · 2026Article
- When to consider mitral valve surgery in dogs: a comparative review of open mitral valve repair and transcatheter edge-to-edge repair with a proposed selection framework.Frontiers in veterinary science · 2026Review
- Validation of deep learning enabled software MetronMind to measure vertebral heart size and vertebral left atrial size in dogs.PloS one · 2026Article
- Effects of a resveratrol-containing nutraceutical on cardiac biomarkers, echocardiographic parameters, and oxidative stress in dogs with naturally occurring cardiac disease.Frontiers in veterinary science · 2026Article
- Predicting stage B2 myxomatous mitral valve disease in dogs using machine learning and routine clinical data.Frontiers in veterinary science · 2026Article
- Quantitative mitral regurgitation and conventional echocardiographic variables in canine myxomatous mitral valve disease.Frontiers in veterinary science · 2026Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 20 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. HYPOTHESIS/
objectivesAdministration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia. ANIMALS: 360 client-owned dogs with MMVD with left atrial-to-aortic ratio ≥1.6, normalized left ventricular internal diameter in diastole ≥1.7, and vertebral heart sum >10.5.
methodsProspective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia.
resultsMedian time to primary endpoint was 1228 days (95% CI: 856-NA) in the pimobendan group and 766 days (95% CI: 667-875) in the placebo group (P = .0038). Hazard ratio for the pimobendan group was 0.64 (95% CI: 0.47-0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the pimobendan group lived longer (median survival time was 1059 days (95% CI: 952-NA) in the pimobendan group and 902 days (95% CI: 747-1061) in the placebo group) (P = .012). CONCLUSIONS AND CLINICAL IMPORTANCE: Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.